Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo de estudio
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Expert Rev Clin Pharmacol ; 17(2): 189-201, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38269492

RESUMEN

BACKGROUND: Metformin has the potential for treating numerous diseases, but there are still many unrecognized and unreported adverse events (AEs). METHODS: We selected data from the United States FDA Adverse Event Reporting System (FAERS) database from the first quarter (Q1) of 2004 to the fourth quarter (Q4) of 2022 for disproportionality analysis to assess the association between metformin and related adverse events. RESULTS: In this study 10,500,295 case reports were collected from the FAERS database, of which 56,674 adverse events related to metformin were reported. A total of 643 preferred terms (PTs) and 27 system organ classes (SOCs) that were significant disproportionality conforming to the four algorithms simultaneously were included. The SOCs included metabolic and nutritional disorders (p = 0.00E + 00), gastrointestinal disorders (p = 0.00E + 00) and others. PT levels were screened for adverse drug reaction (ADR) signals such as acute pancreatitis (p = 0.00E + 00), melas syndrome, pemphigoid (p = 0.00E + 00), skin eruption (p = 0.00E + 00) and drug exposure during pregnancy (p = 0.00E + 00). CONCLUSION: Most of our results were consistent with the specification, but some new signals of adverse reactions such as acute pancreatitis were not included. Therefore, further studies are needed to validate unlabeled adverse reactions and provide important support for clinical monitoring and risk identification of metformin.


Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Metformina , Pancreatitis , Humanos , Estados Unidos , Metformina/efectos adversos , Farmacovigilancia , Enfermedad Aguda , Sistemas de Registro de Reacción Adversa a Medicamentos , United States Food and Drug Administration , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/etiología
2.
Front Biosci (Landmark Ed) ; 29(1): 23, 2024 01 18.
Artículo en Inglés | MEDLINE | ID: mdl-38287801

RESUMEN

Male infertility, age-related changes, and tumors have been increasingly studied in the field of male reproductive health due to the emergence of environmental stressors, declining fertility rates, and aging populations. Numerous studies have demonstrated that the ERK1/2 signaling pathway plays a significant role in male reproduction. The ERK1/2 pathway is associated with several signaling pathways and has a complex interplay that influences the spermatogenic microenvironment, sperm viability, gonadal axis regulation, as well as resistance to testicular aging and tumors. Moreover, the ERK1/2 pathway directly or indirectly regulates testicular somatic cells, which are crucial for maintaining spermatogenesis and microenvironment regulation. Given the critical role of the ERK1/2 signaling pathway in male reproductive health, comprehensive exploration of its multifaceted effects on male reproduction and underlying mechanisms is necessary. This study aims to provide a solid foundation for in-depth research in the field of male reproduction and further enhance the reproductive health of males.


Asunto(s)
Infertilidad Masculina , Neoplasias , Masculino , Humanos , Fertilidad/fisiología , Sistema de Señalización de MAP Quinasas , Semen/metabolismo , Reproducción , Testículo/metabolismo , Infertilidad Masculina/genética , Infertilidad Masculina/metabolismo , Infertilidad Masculina/patología , Transducción de Señal , Neoplasias/metabolismo , Microambiente Tumoral
3.
ACS Omega ; 8(28): 25066-25080, 2023 Jul 18.
Artículo en Inglés | MEDLINE | ID: mdl-37483184

RESUMEN

BACKGROUND: Alzheimer's disease (AD) is the most common neurodegenerative disease, severely reducing the cognitive level and life quality of patients. Byu dMar 25 (BM25) has been proved to have a therapeutic effect on AD. However, the pharmacological mechanism is still unclear. Therefore, this study aims to reveal the potential mechanism of BM25 affecting AD from the perspective of network pharmacology and experimental validation. METHODS: The potential active ingredients of BM25 were obtained from the TCMSP database and literature. Possible targets were predicted using SwissTargetPrediction tools. AD-related genes were identified by using GeneCards, OMIM, DisGeNET, and Drugbank databases. The candidate genes were obtained by extraction of the intersection network. Additionally, the "drug-target-disease" network was constructed by Cytoscape 3.7.2 for visualization. The PPI network was constructed by the STRING database, and the core network modules were filtered by Cytoscape 3.7.2. Enrichment analysis of GO and KEGG was carried out in the Metascape platform. Ledock software was used to dock the critical components with the core target. Furthermore, protein levels were evaluated by immunohistochemistry. RESULTS: In this study, 112 active components, 1112 disease candidate genes, 3084 GO functions, and 277 KEGG pathways were obtained. Molecular docking showed that the effective components of BM25 in treating AD were ß-asarone and hydroxysafflor yellow A. The most important targets were APP, PIK3R1, and PIK3CA. Enrichment analysis indicated that the Golgi genetic regulation, peroxidase activity regulation, phosphatidylinositol 3-kinase complex IA, 5-hydroxytryptamine receptor complexes, cancer pathways, and neuroactive ligand-receptor interactions played vital roles against AD. The rat experiment verified that BM25 affected PI3K-Akt pathway activation in AD. CONCLUSIONS: This study reveals the mechanism of BM25 in treating AD with network pharmacology, which provides a foundation for further study on the molecular mechanism of AD treatment.

4.
J Complement Integr Med ; 17(2)2018 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-30352036

RESUMEN

Background Mind sound resonance technique (MSRT) is a yoga-based relaxation technique. Previous studies on MSRT demonstrated its potential health-benefiting effects in both clinical and nonclinical population. Present study intended to assess the acute effect of MSRT intervention on blood pressure, heart rate (HR), and state anxiety in patients with essential hypertension (HTN). Methods Thirty participants (13 females) with HTN, within the age range 30-60 years (with mean±SD: 57.23±11.3 years), who visited SVYASA University campus to attend 1-week residential yoga program for HTN treatment, were considered for this study based on inclusion and exclusion criteria. All participants received a 4-day MSRT orientation sessions prior to the study. Each participant underwent 30-min session of both MSRT and supine rest (SR) on 2 successive days. Systolic and diastolic blood pressures, pulse rate, and state anxiety were measured before and immediately after both MSRT and SR sessions. Data were analyzed using SPSS version 16. Repeated-measure analysis of variance was applied to assess within-subjects changes. Results After MSRT session, significant decrease in systolic blood pressure (SBP), diastolic blood pressure (DBP), HR, and state anxiety was observed compared to baseline. Similarly, after SR session, significant changes were found in HR and state anxiety. No significant change was seen in SBP and DBP following SR compared to SR session; MSRT session showed significantly better improvement in SBP, DBP, HR, and state anxiety. Conclusion Present study demonstrated the usefulness of single session of MSRT in reducing blood pressure, HR, and state anxiety among individuals with HTN as compared to SR. These findings encourage the further studies with larger sample size and long-term intervention with a robust research design.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA